Dottie Ann Sazon, MD
Pulmonary Disease · National City, CANPI 1033222708
Payments from drug & device makers
Across 139 payments — averaging $81.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Sunovion Pharmaceuticals Inc.$2K
- Boehringer Ingelheim$372
- Harmony Biosciences LLC$240
- Actelion Pharmaceuticals US, Inc.$218
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$7,55066%
- Travel & lodging$731%
- Food & beverage$3,54331%
- Education$2022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $4,082 |
| AstraZeneca | 38 | $3,011 |
| Sunovion Pharmaceuticals Inc. | 4 | $1,850 |
| Boehringer Ingelheim | 16 | $372 |
| Harmony Biosciences LLC | 5 | $240 |
| Actelion Pharmaceuticals US, Inc. | 8 | $218 |
| Noctrix Health, Inc. | 1 | $198 |
| ZOLL Respicardia, Inc. | 1 | $156 |
| Sanofi | 6 | $152 |
| Regeneron Healthcare Solutions, Inc. | 5 | $142 |
| Amarin Pharma, Inc. | 1 | $120 |
| Abbott | 1 | $103 |
| Boston Scientific | 1 | $95 |
| Grifols USA, LLC | 3 | $70 |
| Philips North America LLC | 3 | $68 |
| Baxter Healthcare | 2 | $60 |
| Insmed, Inc. | 3 | $60 |
| Paratek Pharmaceuticals, Inc. | 2 | $50 |
| Advanced Respiratory, Inc | 3 | $48 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Electromed, Inc. | 1 | $36 |
| Resmed Corp | 1 | $33 |
| Lilly USA, LLC | 1 | $30 |
| Circassia Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Bayer | 1 | $20 |
| 3b Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$3,600
- BREZTRI AEROSPHERE$2,358
- LONHALA MAGNAIR$1,818
- NIDRA$198
- remede System$156
- Vascepa$120
- Quadra Assura CRT Defibrillator$103
How this compares
$11,368 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 385 | $426,922 |
| TezspireTezepelumab-Ekko | 25 | $145,223 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $45,499 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $27,112 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $12,238 |
| Spiriva RespimatTiotropium Bromide | 11 | $11,647 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $7,304 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $6,340 |
| Varenicline Tartrate | 28 | $5,602 |
| Fluticasone Propionate | 205 | $4,880 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $4,720 |
| Roflumilast | 50 | $4,335 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,828 |
| Mometasone Furoate | 14 | $3,190 |
| Montelukast Sodium | 190 | $2,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $4,082 | $479,726470 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $3,011 | $157,46136 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $372 | $38,75956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in National City
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.